Inorganic nanoparticle biomolecular corona: Formation, evolution and biological impact

Nanomedicine

Volumn 7, Issue 12, 2012, Pages 1917-1930

  Casals, Eudald ^a   Puntes, Víctor F ^a,b  

^a CATALAN INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY ICN2   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

hard protein corona; inorganic nanoparticles; nanoparticle protein interactions; serum proteins; soft protein corona; Vroman effect

Indexed keywords

ALBUMIN; BOVINE SERUM ALBUMIN; FIBRINOGEN; LIPOSOME; METAL OXIDE; NANOPARTICLE; PLASMA PROTEIN; POLYLACTIC ACID; POLYMER; POLYSTYRENE; SELF ASSEMBLED MONOLAYER;

ADSORPTION; BIOMEDICINE; BLOOD; BODY FLUID; CULTURE MEDIUM; DRUG DELIVERY SYSTEM; EVOLUTION; HYDROPHOBICITY; LYMPH; MOLECULE; MORPHOLOGY; MUCUS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; REVIEW; SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY;

ADSORPTION; ANIMALS; HUMANS; NANOPARTICLES; PROTEIN BINDING; PROTEINS; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84871284406     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.169     Document Type: Review

References (90)

1. Brash JL. Protein adsorption at the solid-solution interface in relation to blood material interactions. ACS Symp. Ser. 343, 490-506 (1987).
2. Leroux JC, Allemann E, De Jaeghere F, Doelker E, Gurny R. Biodegradable nanoparticles - from sustained release formulations to improved site specific drug delivery. J. Control. Release 39(2-3), 339-350 (1996).
3. Leroux JC, Dejaeghere F, Anner B, Doelker E, Gurny R. An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(d,l-lactic acid) nanoparticles by human monocytes. Life Sci. 57(7), 695-703 (1995).
4. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev. 16(2-3), 195-214 (1995).
5. Gref R, Luck M, Quellec P et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B 18(3-4), 301-313 (2000).
6. Luck M, Pistel KF, Li YX et al. Plasma protein adsorption on biodegradable microspheres consisting of poly(d,l-lactide-co-glycolide), poly(l-lactide) or ABA triblock copolymers containing poly(oxyethylene) - influence of production method and polymer composition. J. Control. Release 55(2-3), 107-120 (1998).
7. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61(6), 428-437 (2009).
8. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2(8), 469-478 (2007).
9. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology 151(2), 458-465 (2010).
10. Gref R, Minamitake Y, Peracchia MT et al. Biodegradable long-circulating polymeric nanospheres. Proc. Natl Acad. Sci. USA 263(5153), 1600-1603 (1994).
11. Cedervall T, Lynch I, Lindman S et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104(7), 2050-2055 (2007).
12. Faunce TA, White J, Matthael KI. Integrated research into the nanoparticle-protein corona: a new focus for safe, sustainable and equitable development of nanomedicines. Nanomedicine (Lond.) 3(6), 859-866 (2008).
13. Gessner A, Lieske A, Paulke BR, Muller RH. Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J. Biomed. Mater. Res. A 65A(3), 319-326 (2003).
14. Gessner A, Waicz R, Lieske A et al. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int. J. Pharm. 196(2), 245-249 (2000).
15. Lundqvist M, Stigler J, Elia G et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105(38), 14265-14270 (2008).
16. Moreau JW, Weber PK, Martin MC et al. Extracellular proteins limit the dispersal of biogenic nanoparticles. Proc. Natl Acad. Sci. USA 316(5831), 1600-1603 (2007).
17. Sahoo B, Goswami M, Nag S, Maiti S. Spontaneous formation of a protein corona prevents the loss of quantum dot fluorescence in physiological buffers. Chem. Phys. Lett. 445(4-6), 217-220 (2007).
18. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 4(7), 3623-3632 (2010).
19. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Hardening of the nanoparticle protein corona in metal (Au, Ag) and oxide (Fe3O4, CoO and CeO2) nanoparticles. Small 7(24), 3479-3486 (2011).
20. Dobrovolskaia MA, Patri AK, Zheng JW et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 5(2), 106-117 (2009).
21. Lacerda SH, Park JJ, Meuse C et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 4(1), 365-379 (2010).
22. Rocker C, Potzl M, Zhang F, Parak WJ, Nienhaus GU. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. Nat. Nanotechnol. 4(9), 577-580 (2009).
23. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell "sees" in bionanoscience. J. Am. Chem. Soc. 132(16), 5761-5768 (2010).
24. Ji ZX, Jin X, George S et al. Dispersion and stability optimization of TiO(2) nanoparticles in cell culture media. Environ. Sci. Technol. 44(19), 7309-7314 (2010).
25. Deng ZJ, Mortimer G, Schiller T et al. Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology 20(45), 455101 (2009).
26. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 4(1), 11-18 (2004).
27. Bastus NG, Sanchez-Tillo E, Pujals S et al. Homogeneous conjugation of peptides onto gold nanoparticles enhances macrophage response. ACS Nano 3(6), 1335-1344 (2009).
28. Bastus NG, Sanchez-Tillo E, Pujals S et al. Peptides conjugated to gold nanoparticles induce macrophage activation. Mol. Immunol. 46(4), 743-748 (2009).
29. Podsiadlo P, Sinani VA, Bahng JH et al. Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir 24(2), 568-574 (2008).
30. Byoungjin K, Han G, Toley BJ et al. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat. Nanotechnol. 5(6), 465-472 (2010).
31. Chen JP, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat. Nanotechnol. 1(2), 142-150 (2006).
32. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv. Drug Deliv. Rev. 60(11), 1307-1315 (2008).
33. Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine (Lond.) 2(1), 23-39 (2007).
34. Murphy CJ, Gole AM, Stone JW et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc. Chem. Res. 41(12), 1721-1730 (2008).
35. Prime KL, Whitesides GM. Self-assembled organic monolayers - model systems for
36. Silin V, Weetall H, Vanderah DJ. SPR studies of the nonspecific adsorption kinetics of human IgG and BSA on gold surfaces modified by self-assembled monolayers (SAMs). J. Colloid Interf. Sci. 185(1), 94-103 (1997).
37. Norde W, Lyklema J. Why proteins prefer interfaces. J. Biomater. Sci. Polym. Ed. 2(3), 183-202 (1991).
38. Brash JL, Horbett TA. Proteins at interfaces II. An overview. In: Proteins at Interfaces II. Fundamentals and Applications. Horbett TA, Brash JL (Eds). ACS, DC, USA (1995).
39. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberdorster G, McGrath JL. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 30(4), 603-610 (2009).
40. Mahmoudi M, Lynch I, Ejtehadi MR et al. Protein-nanoparticle interactions: opportunities and challenges. Chem. Rev. 111(9), 5610-5637 (2011).
41. Vroman L. Effect of adsorbed proteins on wettability of hydrophilic and hydrophobic solids. Nature 196(4853), 476-477 (1962).
42. Slack SM, Horbett TA. The Vroman effect - a critical review. In: Proteins at Interfaces II. Horbett TA, Brash JL (Eds). ACS, DC, USA, 112-128 (1995).
43. Alaeddine S, Nygren H. Logarithmic growth of protein films. In: Proteins at Interfaces II. Fundamentals and Applications. Horbett TA, Brash JL (Eds). ACS, DC, USA (1995).
44. Monopoli MP, Walczyk D, Campbell A et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133(8), 2525-2534 (2011).
45. Lundqvist M, Stigler J, Cedervall T et al. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 5(9), 7503-7509 (2011).
46. Ashkarran AA, Ghavami M, Aghaverdi H, Stroeve P, Mahmoudi M. Bacterial effects and protein corona evaluations: crucial ignored factors in the prediction of bio-efficacy of various forms of silver nanoparticles. Chem. Res. Toxicol. doi:10.1021/tx300083s (2012) (Epub ahead of print).
47. Milani S, Bombelli FB, Pitek AS, Dawson KA, Radler J. Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. ACS Nano 6(3), 2532-2541 (2012).
48. Goutelle S, Maurin M, Rougier F et al. The Hill equation: a review of its capabilities in pharmacological modelling. Fund. Clin. Pharmacol. 22(6), 633-648 (2008).
49. Jiang X, Weise S, Hafner M et al. Quantitative analysis of the protein corona on FePt nanoparticles formed by transferrin binding. J. R. Soc. Interface 7(Suppl. 1) S5-S13 (2010).
50. Gebauer JS, Malissek M, Simon S et al. Impact of the nanoparticle-protein corona on colloidal stability and protein structure. Langmuir doi:10.1021/la301104a (2012) (Epub ahead of print).
51. Thode K, Luck M, Semmler W, Muller RH, Kresse M. Determination of plasma protein adsorption on magnetic iron oxides: sample preparation. Pharm. Res. 14(7), 905-910 (1997).
52. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J. Microencapsulation 13(3), 245-255 (1996).
53. Huang J, Bu LH, Xie J et al. Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano 4(12), 7151-7160 (2010).
54. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5(4), 487-495 (2008).
55. Dutta D, Sundaram SK, Teeguarden JG et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol. Sci. 100(1), 303-315 (2007).
56. Slack SM, Horbett TA. Physicochemical and biochemical aspects of fibrinogen adsorption from plasma and binary protein solutions onto polyethylene and glass. J. Colloid Interf. Sci. 124(2), 535-551 (1988).
57. Wojciechowski P, Tenhove P, Brash JL. Phenomenology and mechanism of the transient adsorption of fibrinogen from plasma (Vroman effect). J. Colloid Interf. Sci. 111(2), 455-465 (1986).
58. Kogan MJ, Bastus NG, Amigo R et al. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett. 6(1), 110-115 (2006).
59. Moore NS, Van Slyke DD. The relationships between plasma specific gravity, plasma protein content and edema in nephritis. J. Clin. Invest. 8(3), 337-355 (1930).
60. Lesniak A, Campbell A, Monopoli MP et al. Serum heat inactivation affects protein corona composition and nanoparticle uptake. Biomaterials 31(36), 9511-9518 (2010).
61. Arvizo RR, Giri K, Moyano D et al. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS ONE 7(3), e33650 (2012).
62. Maiorano G, Sabella S, Sorce B et al. Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. ACS Nano 4(12), 7481-7491 (2010).
63. Deng ZJ, Liang MT, Monteiro M, Toth I, Minchin RF. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotechnol. 6(1), 39-44 (2011).
64. Norde W. Adsorption of proteins from solution at the solid-liquid interface. Adv. Colloid Interface Sci. 25(4), 267-340 (1986).
65. Bally M, Voros J. Nanoscale labels: nanoparticles and liposomes in the development of high-performance biosensors. Nanomedicine (Lond.) 4(4), 447-467 (2009).
66. Hirsch LR, Jackson JB, Lee A, Halas NJ, West J. A whole blood immunoassay using gold nanoshells. Anal. Chem. 75(10), 2377-2381 (2003).
67. Liu X, Dai Q, Austin L et al. A one-step homogeneous immunoassay for cancer biomarker detection using gold nanoparticle probes coupled with dynamic light scattering. J. Am. Chem. Soc. 130(9), 2780-2782 (2008).
68. Sanfins E, Dairou J, Rodrigues-Lima F, Dupret JM. Nanoparticle-protein interactions: from crucial plasma proteins to key enzymes. J. Phys. 304, 012039 (2011).
69. Roach P, Farrar D, Perry CC. Interpretation of protein adsorption: surface-induced conformational changes. J. Am. Chem. Soc. 127(22), 8168-8173 (2005).
70. Zhang DM, Neumann O, Wang H et al. Gold nanoparticles can induce the formation of protein-based aggregates at physiological pH. Nano Lett. 9(2), 666-671 (2009).
71. Billsten P, Freskgard PO, Carlsson U, Jonsson BH, Elwing H. Adsorption to silica nanoparticles of human carbonic anhydrase II and truncated forms induce a molten-globule-like structure. FEBS Lett 402(1), 67-72 (1997).
72. Karlsson M, Martensson LG, Jonsson BH, Carlsson U. Adsorption of human carbonic anhydrase II variants to silica nanoparticles occur stepwise: binding is followed by successive conformational changes to a molten-globule-like state. Langmuir 16(22), 8470-8479 (2000).
73. Lundqvist M, Sethson I, Jonsson BH. Transient interaction with nanoparticles "freezes" a protein in an ensemble of metastable near-native conformations. Biochemistry 44(30), 10093-10099 (2005).
74. Fei L, Perrett S. Effect of nanoparticles on protein folding and fibrillogenesis. Int. J. Molec. Sci. 10(2), 646-655 (2009).
75. Goy-Lopez S, Juarez J, Alatorre-Meda M et al. Physicochemical characteristics of protein- NP bioconjugates: the role of particle curvature and solution conditions on human serum albumin conformation and fibrillogenesis inhibition. Langmuir 28(24), 9113-9126 (2012).
76. O'Shaughnessy JA, Tjulandin S, Davidson N. ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: a Phase III trial. Presented at: 26th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 3-6 December 2003.
77. Buckton G. Drug targeting and delivery. In: Interfacial Phenomena in Drug Delivery and Targeting. CRC Press, FL, USA, 237-281 (1995).
78. Keogh JR, Velander FF, Eaton JW. Albumin-binding surfaces for implantable devices. J. Biomed. Mater. Res. 26(4), 441-456 (1992).
79. Robidoux A, Buyse M, Buzdar A et al. Neoadjuvant chemotherapy with sequential weekly nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane (R)) followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in locally advanced breast cancer (LABC): a Phase II trial of the NSABP Foundation Research Programs (FRP). Breast Cancer Res. Tr. 100, S147 (2006).
80. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL(R)- free formulation of paclitaxel. Nanomedicine (Lond.) 2(4), 415-423 (2007).
81. Gonzalo T, Talman EG, de Ven AV et al. Selective targeting of pentoxifylline platinum-based to hepatic stellate cells using a novel linker technology. J. Control. Release 111(1-2), 193-203 (2006).
82. Moghimi SM. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim. Biophys. Acta 1590(1-3), 131-139 (2002).
83. Temming K, Lacombe M, van der Hoeven P et al. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology. Bioconjugate Chem. 17(5), 1246-1255 (2006).
84. Fan CH, Hu WB, Peng C et al. Protein corona-mediated mitigation of cytotoxicity of graphene oxide. ACS Nano 5(5), 3693-3700 (2011).
85. Hoet PH, Gilissen L, Nemery B. Polyanions protect against the in vitro pulmonary toxicity of polycationic paint components associated with the Ardystil syndrome. Toxicol. Appl. Pharmacol. 175(2), 184-190 (2001).
86. Ebbesen P. DEAE-dextran and polybrene cation enhancement and dextran sulfate anion inhibition of immune cytolysis. J. Immunol. 109(6), 1296-1299 (1972).
87. Morgan DM, Larvin VL, Pearson JD. Biochemical characterization of polycation-induced cytotoxicity to human vascular endothelial cells. J. Cell Sci. 94(3), 553-559 (1989).
88. Balogh L, Nigavekar SS, Nair BM et al. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedicine 3(4), 281-296 (2007).
89. Tan YD, Li S, Pitt BR, Huang L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum. Gene Ther. 10(13), 2153-2161 (1999).
90. Casals E, Vazquez-Campos S, Bastus NG, Puntes V. Distribution and potential toxicity of engineered inorganic nanoparticles and carbon nanostructures in biological systems. Trac-Trend. Anal. Chem. 27(8), 672-683 (2008).